OS Therapies (OSTX) Total Liabilities (2023 - 2026)
OS Therapies' (OSTX) quarterly Total Liabilities came in at $17.1 million in Q1 2026, up 368.96% YoY from $3.6 million in Q1 2025, and up 43.73% on a QoQ basis from $11.9 million in Q4 2025.
OS Therapies (OSTX) Total Liabilities (2023 - 2026) Analysis & Trends
OS Therapies (OSTX) has 4 years of Total Liabilities data on file, last reported at $17.1 million in Q1 2026.
- Quarterly Total Liabilities rose 368.96% year-over-year to $17.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.1 million (up 368.96% YoY) and the FY2025 annual result came in at $11.9 million, up 150.98% from the prior year.
- Total Liabilities advanced to $17.1 million in Q1 2026, from $11.9 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $28.4 million in Q2 2024 to a low of $2.7 million in Q3 2024.
- A 4-year average of $12.8 million and a median of $8.3 million in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2025 — Total Liabilities tumbled 87.47% — and 2026, when it surged 368.96%.
- Tracing OSTX's Total Liabilities over 4 years: stood at $24.8 million in 2023, then plunged by 80.95% to $4.7 million in 2024, then soared by 150.98% to $11.9 million in 2025, then jumped by 43.73% to $17.1 million in 2026.
- The last three Total Liabilities figures came in at $17.1 million (Q1 2026), $11.9 million (Q4 2025), and $4.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.97 Bn | 132.12 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.64 Bn | 78.64 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.55 Bn | 60.37 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 61.26 Bn | 56.12 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.30 Bn | 37.20 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.66 Bn | 28.35 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.68 Bn | 10.29 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 10.03 Bn |
| 10 | OS Therapies | 19.94 Mn | 19.94 Mn | - | 20.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.05 Mn |
| Dec 31, 2025 | 11.86 Mn |
| Sep 30, 2025 | 4.25 Mn |
| Jun 30, 2025 | 3.56 Mn |
| Mar 31, 2025 | 3.64 Mn |
| Dec 31, 2024 | 4.73 Mn |
| Sep 30, 2024 | 2.68 Mn |
| Jun 30, 2024 | 28.41 Mn |
| Mar 31, 2024 | 26.56 Mn |
| Dec 31, 2023 | 24.81 Mn |